KMT2A and acute lymphoblastic leukemia: We recently identified HDAC7 to be a novel biomarker and prognostic factor in infants (<1-year-olds) with pro-B acute lymphoblastic leukemia (pro-B-ALL) and MLL-AF4 rearrangement (27).